Neurocrine Biosciences (NBIX) Common Equity (2009 - 2026)
Neurocrine Biosciences' Common Equity was $3.88 billion in Q3 2026, up 29.1% from $3 billion a year earlier and up 5.0% from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Common Equity (2009 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Neurocrine Biosciences came in at $3.25 billion, up 25.6% from FY2024.
- Common Equity has now increased for nine consecutive years, with a five-year compound annual growth rate of 23.6% (FY2020 to FY2025).
- In earlier years, Common Equity was $2.59 billion in FY2024 (+16.0%), $2.23 billion in FY2023 (+30.7%), $1.71 billion in FY2022 (+24.3%) and $1.37 billion in FY2021 (+22.0%).
- The Q3 2026 figure marks the highest quarterly Common Equity in data going back to Q4 2010.
- Compared with a year earlier, Common Equity has increased for 36 straight quarters, with growth averaging 20.8% over the last eight quarters.
- Across the past five years, year-over-year growth in Common Equity ran from 6.3% in Q1 2025 to 41.7% in Q1 2024.
- Per Business Quant data, NBIX's Common Equity in the three quarters before Q3 2026 was $3.69 billion (Q2 2026), $3.41 billion (Q1 2026) and $3.25 billion (Q4 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 40.27 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 81.53 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | -4.58 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 44.95 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 51.81 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 14.35 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 13.04 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 89.30 Bn |
| 10 | Neurocrine Biosciences | 17.13 Bn | 13.21 Bn | 1.10 Bn | 3.88 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 3.88 Bn |
| Jun 30, 2026 | 3.69 Bn |
| Mar 31, 2026 | 3.41 Bn |
| Dec 31, 2025 | 3.25 Bn |
| Sep 30, 2025 | 3.00 Bn |
| Jun 30, 2025 | 2.69 Bn |
| Mar 31, 2025 | 2.54 Bn |
| Dec 31, 2024 | 2.59 Bn |
| Sep 30, 2024 | 2.72 Bn |
| Jun 30, 2024 | 2.51 Bn |
| Mar 31, 2024 | 2.39 Bn |
| Dec 31, 2023 | 2.23 Bn |
| Sep 30, 2023 | 2.00 Bn |
| Jun 30, 2023 | 1.85 Bn |
| Mar 31, 2023 | 1.68 Bn |
| Dec 31, 2022 | 1.71 Bn |
| Sep 30, 2022 | 1.54 Bn |
| Jun 30, 2022 | 1.42 Bn |
| Mar 31, 2022 | 1.39 Bn |
| Dec 31, 2021 | 1.37 Bn |
API Access
Neurocrine Biosciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();